DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

A Diabetes Outcomes Progression Trial

ADOPT logo


Publications (9 of 9)


Search Publications :

2011

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
John M. Lachin, Giancarlo Viberti, Bernard Zinman, Steven M. Haffner, R. Paul Aftring, Gitanjali Paul, Barbara G. Kravitz, William H. Herman, Rury R. Holman, Steven E. Kahn, ADOPT
Clin J Am Soc Nephrol 2011;6:1032-40. Published:May-2011. Epub:31-Mar-2011. PMID:21454723. doi:10.2215/CJN.09291010

Effects Of Rosiglitazone, Glyburide, and Metformin on beta-Cell Function and Insulin Sensitivity in ADOPT
Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; and the ADOPT Study Group
Diabetes 2011;60:1552-1560. Published:May-2011. Epub:17-Mar-2011. PMID:21415383. doi:10.2337/db10-1392

2010

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)
Steven E. Kahn, Steven M. Haffner, Giancarlo Viberti, William H. Herman, John M. Lachin, Barbara G. Kravitz, Dahong Yu, Gitanjali Paul, Rury R. Holman, Bernard Zinman and for the ADOPT Study Group
Diabetes Care 2010;33:177-183. Published:Jan-2010. Epub:06-Oct-2009. PMID:19808911. doi:10.2337/dc09-1661
[Abstract]

2009

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Bernard Zinman, Steven M. Haffner, William H. Herman, Rury R. Holman, John M. Lachin, Barbara G. Kravitz, Gitanjali Paul, Nigel P. Jones, R. Paul Aftring, Giancarlo Viberti, Steven E. Kahn, and the A Diabetes Outcome Progression Trial Study Group
J Clin Endocrinol Metab 2009;95:134-142. Published:Jan-2010. Epub:29-Oct-2009. PMID:19875477. doi:10.1210/jc.2009-0572

2006

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G for the ADOPT Study Group
N Eng J Med 2006;355:2427-43. Published:07-Dec-2006. Epub:04-Dec-2006. PMID:17145742. doi:10.1056/NEJMoa066224
[Abstract] [Slides]
Erratum in :
N Eng J Med 2007;356:1387-8, Print:29-Mar-2007, doi:10.1056/NEJMx070014

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH for the ADOPT Study Group
Diabetic Medicine 2006;23:1289-1294. Published:Dec-2006. Epub:17-Nov-2006. PMID:17116177. doi:10.1111/j.1464-5491.2006.02022.x
[Abstract]

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC and the ADOPT Study Group
Diabetes 2006;55:2357-2364. Published:Aug-2006. PMID:16873701. doi:10.2337/db06-0116
[Abstract]

2004

Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe
Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group
Diabetes 2004;53:3193-3200. Published:22-Sep-2006. PMID:15561950. doi:10.2337/diabetes.53.12.3193
[Abstract]

2002

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
Viberti G. Kahn SE. Greene DA. Herman WH. Zinman B. Holman RR. Haffner SM. Levy D. Lachin JM. Berry RA. Heise MA. Jones NP. Freed MI.
Diabetes Care 2002;25:1737-1743. Published:Oct-2002. PMID:12351470. doi:10.2337/diacare.25.10.1737
[Abstract]